Richard A. Cramer Alice D. Cramer Warren K. Boynton Susi M. Boynton Kevin P. Monaghan Dina A. Monaghan v. Commissioner, Internal Revenue Service

64 F.3d 1406, 95 Daily Journal DAR 12241, 95 Cal. Daily Op. Serv. 7149, 76 A.F.T.R.2d (RIA) 6482, 1995 U.S. App. LEXIS 25337, 1995 WL 530233
CourtCourt of Appeals for the Ninth Circuit
DecidedSeptember 11, 1995
Docket94-70066
StatusPublished
Cited by47 cases

This text of 64 F.3d 1406 (Richard A. Cramer Alice D. Cramer Warren K. Boynton Susi M. Boynton Kevin P. Monaghan Dina A. Monaghan v. Commissioner, Internal Revenue Service) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Richard A. Cramer Alice D. Cramer Warren K. Boynton Susi M. Boynton Kevin P. Monaghan Dina A. Monaghan v. Commissioner, Internal Revenue Service, 64 F.3d 1406, 95 Daily Journal DAR 12241, 95 Cal. Daily Op. Serv. 7149, 76 A.F.T.R.2d (RIA) 6482, 1995 U.S. App. LEXIS 25337, 1995 WL 530233 (9th Cir. 1995).

Opinion

BRUNETTI, Circuit Judge:

Richard and Alice Cramer, Warren and Susi Boynton, and Kevin and Dina Monaghan appeal from a decision of the Tax Court upholding deficiencies and various penalties assessed by the Commissioner of Internal Revenue against their 1982 federal income tax payments. We have jurisdiction pursuant to I.R.C. § 7482(a), and we affirm.

FACTS AND PROCEEDINGS BELOW

In 1972, Richard Cramer founded IMED Corp., a company that designed, manufactured and sold electronic medical instruments. Cramer served as president and chief executive officer of IMED from its inception until 1982. During that time, Warren Boynton served as vice-president, and Kevin Monaghan, an attorney, served as outside general counsel. All three also served at various times on the board of directors of IMED.

From 1978 to 1981, the stock of IMED was neither publicly traded on an established exchange, nor registered with the Securities and Exchange Commission. During that time, that stock was held by approximately 150 to 250 shareholders. In 1978, IMED issued to Cramer an option to purchase 50,-000 shares of IMED stock at $50 per share. The terms of the option provided certain vesting restrictions: Cramer could only exercise the option in 20% increments in each of the next five years, and only so long as he remained employed by IMED. The terms also provided certain transfer restrictions: Cramer could only transfer the option to persons approved by the board as “qualified offerees,” and any transferee would take the option subject to the vesting restrictions.

In 1979, IMED issued to Cramer an option to purchase 4390 shares of IMED stock at $8 per share, to Boynton an option to purchase 30,000 shares of IMED stock at $13 per share, and to Monaghan an option to purchase 4500 shares at $13 per share. All of these options provided for a five year vesting schedule and were subject to the same vesting and transfer restrictions as Cramer’s 1978 option.

In 1981, on the advice of- Monaghan, IMED and Privaco Trust Services S.A., as trustee, entered into a stock option trust agreement. The named beneficiaries included Cramer, Boynton, Monaghan and the other directors of IMED. In 1981, IMED issued to the trustee an option to purchase 325,000 paired shares of IMED stock at various prices. The terms of the option provided that the trustee could not transfer the option except to a beneficiary. Those terms also provided that the option could only be exercised in increments in 1983, 1984 and 1985. A separate agreement among the beneficiaries of the trust provided that each beneficiary could be divested of his allocable share of the option if he were no longer employed by IMED on the vesting dates.

IMED issued all of these options in recognition of the services Cramer, Boynton and Monaghan provided to the company. The delayed vesting schedules and restrictions were intended to induce their continued employment with IMED. Appellants never exercised any part of the options.

In 1978, Dan Hendrickson, the corporate comptroller and treasurer of IMED, consulted with an accountant at Arthur Young & Co. regarding the tax treatment of these options. The accountant did not actually review the IMED options. Nonetheless, he informed Hendrickson that as a general matter, I.R.C. § 83(b) elections could be filed to *1409 include the value of so-called “nonstatutory options” (options not subject to I.R.C. § 422), such as the IMED options, in ordinary income at the time of grant, even if they were not publicly traded, and that the options would then receive capital gains treatment upon later disposition.

On the basis of that information, as well as his own research, Hendrickson advised Cramer, Boynton and Monaghan that on the one hand, statements in the legislative history of the 1976 Tax Reform Act arguably supported treating the IMED options in this manner. He told them that in order to have a chance at receiving capital gain treatment upon future disposition of the options, they would have to file § 83(b) elections with the Internal Revenue Service to include their value in ordinary income in the year of grant. But he told them that on the other hand, under Treasury regulations, he believed that the value of the options could not be readily ascertained upon grant. If that were the case, § 83 would not apply at grant at all. He advised them that pursuant to those regulations, the IRS could take the position that the options would not receive capital gains treatment upon future disposition. He further informed them that acting contrary to or overturning a Treasury regulation “is very difficult.”

In an attempt to ensure capital gain treatment upon future disposition of the options, appellants filed § 83(b) elections with the IRS for Cramer’s 1978 option, Boynton’s 1979 option and Monaghan’s 1979 option. The elections stated that the fair market value of the options at the date of grant was zero. No such elections were filed either for Cramer’s 1979 option or for the 1981 option issued to the trust. Appellants reported no taxable income in the year of grant from the receipt of any of the options.

Despite filing elections declaring that the options had zero value, Cramer believed that the options had a value greater than zero upon grant. Boynton believed that options had value upon grant, but that it was not “readily recognizable value.” Appellants did not consult an expert on options or valuation before they claimed that value as zero.

In 1981, John Stine of Arthur Young began handling IMED’s tax matters. At that time, appellants inquired whether the statute of limitations on their treatment of the options would run from the time when they filed the § 83(b) elections. Stine determined that it would not, and also sent a letter to Mona-ghan stating:

IMED currently takes the position that its stock options are governed by Section 83 and therefore the present tax treatment is ... no income to the employee on grant or exercise and no compensation deduction to IMED. However, Regulation 1.83-7 states that an option must have a “readily ascertainable fair market value” before § 83 will apply. Since the definition of “readily ascertainable fair market value” is virtually impossible to meet, IMED’s present position is subject to challenge.

He suggested that IMED consider changing its position in light of the potential exposure to exercising employees, should the IRS successfully assert the nonapplication of § 83 at grant. Monaghan discussed Stine’s letter with Cramer.

In 1982, Warner-Lambert Corp. purchased all of the stock of IMED for approximately $163 per share. As part of the agreement, the officers and directors of IMED resigned. Warner-Lambert also agreed to buy all outstanding vested and nonvested options on IMED stock. Warner-Lambert paid appellants approximately $163 less the exercise price for each option. Cramer received $25,946,506 for all of his options; Boynton received $7,714,800 for his options; and Monaghan received $2,273,895 for his.

Tax professionals prepared all of appellants’ 1982 federal income tax returns. Those professionals informed appellants that they had a plausible position that gain on the options was capital gain, but that Treasury regulations were to the contrary. They said that there was a risk the IRS would reach a contrary conclusion.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Strom v. United States
641 F.3d 1051 (Ninth Circuit, 2011)
Fisher v. United States
82 Fed. Cl. 780 (Federal Claims, 2008)
Arberg v. Comm'r
2007 T.C. Memo. 244 (U.S. Tax Court, 2007)
Thrane v. Comm'r
2006 T.C. Memo. 269 (U.S. Tax Court, 2006)
United States v. James H. Tuff
469 F.3d 1249 (Ninth Circuit, 2006)
United States v. Tuff
Ninth Circuit, 2006
Hubbard v. United States
209 F. App'x 660 (Ninth Circuit, 2006)
Gleason v. Comm'r
2006 T.C. Memo. 191 (U.S. Tax Court, 2006)
Richardson v. Comm'r
2006 T.C. Memo. 69 (U.S. Tax Court, 2006)
Deihl v. Comm'r
2005 T.C. Memo. 287 (U.S. Tax Court, 2005)
Hubbard v. United States
359 F. Supp. 2d 1123 (W.D. Washington, 2005)
Heller-Loren v. Apuzzio
853 A.2d 997 (New Jersey Superior Court App Division, 2004)
Megibow v. Comm'r
2004 T.C. Memo. 41 (U.S. Tax Court, 2004)
Perry Funeral Home, Inc. v. Comm'r
2003 T.C. Memo. 340 (U.S. Tax Court, 2003)
MARX v. COMMISSIONER
2003 T.C. Summary Opinion 23 (U.S. Tax Court, 2003)
Paul E. Farrell Frances G. Farrell v. United States
313 F.3d 1214 (Ninth Circuit, 2002)
Henry v. Commissioner
34 F. App'x 342 (Ninth Circuit, 2002)
CORCORAN v. COMMISSIONER
2002 T.C. Memo. 18 (U.S. Tax Court, 2002)
LEBOUEF v. COMMISSIONER
2001 T.C. Memo. 261 (U.S. Tax Court, 2001)
XUNCAX v. COMMISSIONER
2001 T.C. Memo. 226 (U.S. Tax Court, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
64 F.3d 1406, 95 Daily Journal DAR 12241, 95 Cal. Daily Op. Serv. 7149, 76 A.F.T.R.2d (RIA) 6482, 1995 U.S. App. LEXIS 25337, 1995 WL 530233, Counsel Stack Legal Research, https://law.counselstack.com/opinion/richard-a-cramer-alice-d-cramer-warren-k-boynton-susi-m-boynton-kevin-ca9-1995.